Negative symptoms and neurocognition in drug-naïve schizophrenia: moderating role of plasma neutrophil gelatinase-associated lipocalin (NGAL) and interferon-gamma (INF-γ).
Saved in:
| Title: | Negative symptoms and neurocognition in drug-naïve schizophrenia: moderating role of plasma neutrophil gelatinase-associated lipocalin (NGAL) and interferon-gamma (INF-γ). |
|---|---|
| Authors: | Li, Meijuan (AUTHOR), Luo, Guoshuai (AUTHOR), Qiu, Yuying (AUTHOR), Zhang, Xue (AUTHOR), Sun, Xiaoxiao (AUTHOR), Li, Yanzhe (AUTHOR), Zhao, Yongping (AUTHOR), Sun, Wei (AUTHOR), Yang, Shu (AUTHOR), Li, Jie (AUTHOR) |
| Source: | European Archives of Psychiatry & Clinical Neuroscience. Aug2024, Vol. 274 Issue 5, p1071-1081. 11p. |
| Subjects: | Lipocalin-2, NF-kappa B, Interferon gamma, Schizophrenia, Symptoms |
| Abstract: | Previous studies reported that peripheral inflammation was associated with cognitive performance and brain structure in schizophrenia. However, the moderating effect of inflammation has not been extensively studied. This study investigated whether inflammation markers moderated the association between negative symptoms and neurocognition in schizophrenia. This cross-sectional study included 137 drug-naïve schizophrenia patients (DNS) and 67 healthy controls (HC). We performed the Measurements and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) for cognitive assessment and the Positive and Negative Syndrome Scale (PANSS) for psychiatric symptoms. Plasma concentrations of interferon-gamma (IFN-γ), neutrophil gelatinase-associated lipocalin (NGAL), and nuclear factor kappa B (NF-κB) were measured. The MCCB neurocognition score, social cognition score, and total score; the plasma concentrations of NGAL, IFN-γ, and NF-κB were significantly decreased in DNS than in HC (all P's < 0.001). PANSS negative subscale (PNS), PANSS reduced expressive subdomain (RES) negatively correlated with neurocognition score (P = 0.007; P = 0.011, respectively). Plasma concentrations of IFN-γ and NGAL positively correlated with neurocognition score (P = 0.043; P = 0.008, relatively). The interactions of PNS × NGAL; PNS × IFN-γ; RES × IFN-γ accounted for significant neurocognition variance (P = 0.025; P = 0.029, P = 0.007, respectively). Simple slope analysis showed that all the above moderating effects only occurred in patients with near normal IFN-γ and NGAL levels. Plasma concentrations of IFN-γ and NGAL moderated the relationship between negative symptoms (especially RES) and neurocognition in schizophrenia. Treatment targeting inflammation may contribute to neurocognition improvement in schizophrenia. [ABSTRACT FROM AUTHOR] |
| Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 178293863 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Negative symptoms and neurocognition in drug-naïve schizophrenia: moderating role of plasma neutrophil gelatinase-associated lipocalin (NGAL) and interferon-gamma (INF-γ). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Li%2C+Meijuan%22">Li, Meijuan</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Luo%2C+Guoshuai%22">Luo, Guoshuai</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Qiu%2C+Yuying%22">Qiu, Yuying</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhang%2C+Xue%22">Zhang, Xue</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sun%2C+Xiaoxiao%22">Sun, Xiaoxiao</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Yanzhe%22">Li, Yanzhe</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhao%2C+Yongping%22">Zhao, Yongping</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sun%2C+Wei%22">Sun, Wei</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yang%2C+Shu%22">Yang, Shu</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Jie%22">Li, Jie</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22European+Archives+of+Psychiatry+%26+Clinical+Neuroscience%22">European Archives of Psychiatry & Clinical Neuroscience</searchLink>. Aug2024, Vol. 274 Issue 5, p1071-1081. 11p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Lipocalin-2%22">Lipocalin-2</searchLink><br /><searchLink fieldCode="DE" term="%22NF-kappa+B%22">NF-kappa B</searchLink><br /><searchLink fieldCode="DE" term="%22Interferon+gamma%22">Interferon gamma</searchLink><br /><searchLink fieldCode="DE" term="%22Schizophrenia%22">Schizophrenia</searchLink><br /><searchLink fieldCode="DE" term="%22Symptoms%22">Symptoms</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Previous studies reported that peripheral inflammation was associated with cognitive performance and brain structure in schizophrenia. However, the moderating effect of inflammation has not been extensively studied. This study investigated whether inflammation markers moderated the association between negative symptoms and neurocognition in schizophrenia. This cross-sectional study included 137 drug-naïve schizophrenia patients (DNS) and 67 healthy controls (HC). We performed the Measurements and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) for cognitive assessment and the Positive and Negative Syndrome Scale (PANSS) for psychiatric symptoms. Plasma concentrations of interferon-gamma (IFN-γ), neutrophil gelatinase-associated lipocalin (NGAL), and nuclear factor kappa B (NF-κB) were measured. The MCCB neurocognition score, social cognition score, and total score; the plasma concentrations of NGAL, IFN-γ, and NF-κB were significantly decreased in DNS than in HC (all P's < 0.001). PANSS negative subscale (PNS), PANSS reduced expressive subdomain (RES) negatively correlated with neurocognition score (P = 0.007; P = 0.011, respectively). Plasma concentrations of IFN-γ and NGAL positively correlated with neurocognition score (P = 0.043; P = 0.008, relatively). The interactions of PNS × NGAL; PNS × IFN-γ; RES × IFN-γ accounted for significant neurocognition variance (P = 0.025; P = 0.029, P = 0.007, respectively). Simple slope analysis showed that all the above moderating effects only occurred in patients with near normal IFN-γ and NGAL levels. Plasma concentrations of IFN-γ and NGAL moderated the relationship between negative symptoms (especially RES) and neurocognition in schizophrenia. Treatment targeting inflammation may contribute to neurocognition improvement in schizophrenia. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=178293863 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00406-023-01650-6 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 11 StartPage: 1071 Subjects: – SubjectFull: Lipocalin-2 Type: general – SubjectFull: NF-kappa B Type: general – SubjectFull: Interferon gamma Type: general – SubjectFull: Schizophrenia Type: general – SubjectFull: Symptoms Type: general Titles: – TitleFull: Negative symptoms and neurocognition in drug-naïve schizophrenia: moderating role of plasma neutrophil gelatinase-associated lipocalin (NGAL) and interferon-gamma (INF-γ). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Li, Meijuan – PersonEntity: Name: NameFull: Luo, Guoshuai – PersonEntity: Name: NameFull: Qiu, Yuying – PersonEntity: Name: NameFull: Zhang, Xue – PersonEntity: Name: NameFull: Sun, Xiaoxiao – PersonEntity: Name: NameFull: Li, Yanzhe – PersonEntity: Name: NameFull: Zhao, Yongping – PersonEntity: Name: NameFull: Sun, Wei – PersonEntity: Name: NameFull: Yang, Shu – PersonEntity: Name: NameFull: Li, Jie IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: Aug2024 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 09401334 Numbering: – Type: volume Value: 274 – Type: issue Value: 5 Titles: – TitleFull: European Archives of Psychiatry & Clinical Neuroscience Type: main |
| ResultId | 1 |
